| Field | Row 1 |
|---|---|
| adsh | 0001823239-25-000063 |
| cik | 1823239 |
| name | MARAVAI LIFESCIENCES HOLDINGS, INC. |
| sic | 2834 |
| countryba | US |
| stprba | CA |
| cityba | SAN DIEGO |
| zipba | 92121 |
| bas1 | 10770 WATERIDGE CIRCLE SUITE 200 |
| bas2 | |
| baph | (858) 546-0004 |
| countryma | US |
| stprma | CA |
| cityma | SAN DIEGO |
| zipma | 92121 |
| mas1 | 10770 WATERIDGE CIRCLE SUITE 200 |
| mas2 | |
| countryinc | US |
| stprinc | DE |
| ein | 000000000 |
| former | |
| changed | |
| afs | 1-LAF |
| wksi | 0 |
| fye | 1231 |
| form | 10-Q |
| period | 20250331 |
| fy | 2025 |
| fp | Q1 |
| filed | 20250512 |
| accepted | 2025-05-12 16:29:00.0 |
| prevrpt | 0 |
| detail | 1 |
| instance | mrvi-20250331_htm.xml |
| nciks | 1 |
| aciks |
| Field Name | Field Description |
|---|---|
| adsh | Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission. |
| cik | Central Index Key (CIK). Ten digit number assigned by the SEC to each registrant that submits filings. |
| name | Name of registrant. This corresponds to the name of the legal entity as recorded in EDGAR as of the filing date. |
| sic | Standard Industrial Classification (SIC). Four digit code assigned by the SEC as of the filing date, indicating the registrant’s type of business. |
| countryba | The ISO 3166-1 country of the registrant's business address. |
| stprba | The state or province of the registrant’s business address, if field countryba is US or CA. |
| cityba | The city of the registrant's business address. |
| zipba | The zip code of the registrant’s business address. |
| bas1 | The first line of the street of the registrant’s business address. |
| bas2 | The second line of the street of the registrant’s business address. |
| baph | The phone number of the registrant’s business address. |
| countryma | The ISO 3166-1 country of the registrant's mailing address. |
| stprma | The state or province of the registrant’s mailing address, if field countryma is US or CA. |
| cityma | The city of the registrant's mailing address. |
| zipma | The zip code of the registrant’s mailing address. |
| mas1 | The first line of the street of the registrant’s mailing address. |
| mas2 | The second line of the street of the registrant’s mailing address. |
| countryinc | The ISO 3166-1 country of incorporation for the registrant. |
| stprinc | The state or province of incorporation for the registrant, if countryinc is US or CA. |
| ein | Employee Identification Number, 9 digit identification number assigned by the Internal Revenue Service to business entities operating in the United States. |
| former | Most recent former name of the registrant, if any. |
| changed | Date of change from the former name, if any. |
| afs | Filer status with the SEC at the time of submission: 1-LAF=Large Accelerated, 2-ACC=Accelerated, 3-SRA=Smaller Reporting Accelerated, 4-NON=Non-Accelerated, 5-SML=Smaller Reporting Filer, NULL=not assigned. |
| wksi | Well Known Seasoned Issuer (WKSI). An issuer that meets specific SEC requirements at some point during a 60-day period preceding the date the issuer satisfies its obligation to update its shelf registration statement. |
| fye | Fiscal Year End Date, rounded to nearest month-end. |
| form | The submission type of the registrant’s filing. |
| period | Balance Sheet Date, rounded to nearest month-end. |
| fy | Fiscal Year Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8). |
| fp | Fiscal Period Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8) within Fiscal Year. |
| filed | The date of the registrant’s filing with the Commission. |
| accepted | The acceptance date and time of the registrant’s filing with the Commission. |
| prevrpt | Previous Report – TRUE indicates that the submission information was subsequently amended. |
| detail | TRUE indicates that the XBRL submission contains quantitative disclosures within the footnotes and schedules at the required detail level (e.g., each amount). |
| instance | The name of the submitted XBRL Instance Document. The name often begins with the company ticker symbol. |
| nciks | Number of Central Index Keys (CIK) of registrants (i.e., business units) included in the consolidating entity’s submitted filing. |
| aciks | Additional CIKs of co-registrants included in a consolidating entity’s EDGAR submission, separated by spaces. If there are no other co-registrants (i.e., nciks=1), the value of aciks is NULL. For a very small number of filers, the entire list of co-registrants is too long to fit in the field. Where this is the case, users should refer to the complete submission file for all CIK information. |
| adsh | ddate | tag | value | uom | qtrs | version | segments | coreg | footnote |
|---|---|---|---|---|---|---|---|---|---|
| 0001823239-25-000063 | 20250331 | Accrued Receivable For Capital Expenditures To Be Reimbursed Under Government Contract | 0.0000 | USD | 1 | 0001823239-25-000063 | |||
| 0001823239-25-000063 | 20240331 | Amortization Of Intangible Assets | 6869000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20240331 | Amortization Of Intangible Assets | 700000.0000 | USD | 1 | us-gaap/2024 | Income Statement Location= Selling General And Administrative Expenses; | ||
| 0001823239-25-000063 | 20250331 | Assets | 959751000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20241231 | Cash And Cash Equivalents At Carrying Value | 322399000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20240331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | -13271000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20240331 | Profit Loss | -22680000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20250331 | Change In Unrealized Gain Loss On Fair Value Hedging Instruments1 | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20250331 | Common Stock Shares Authorized | 500000000.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Common Class A; | ||
| 0001823239-25-000063 | 20241231 | Common Stock Shares Outstanding | 141976000.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Common Class A; Equity Components= Common Stock; | ||
| 0001823239-25-000063 | 20241231 | Contract With Customer Liability Current | 2375000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20240331 | Cost Of Revenue | 38335000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20241231 | Derivative Assets Current | 1375000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20240331 | Earnings Per Share Diluted | -0.0900 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20250331 | Earnings Per Share Diluted | -0.2100 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20241231 | Goodwill | 159878000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20250331 | Goodwill Impairment Loss | 12435000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20250331 | Goodwill Impairment Loss | 12435000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Nucleic Acid Production Segment; | ||
| 0001823239-25-000063 | 20250331 | Inventory Net | 49773000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20240331 | Investment Income Interest | 7210000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20240331 | Minority Interest Period Increase Decrease | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20240331 | Minority Interest Period Increase Decrease | -1510000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Noncontrolling Interest; | ||
| 0001823239-25-000063 | 20240331 | Net Cash Provided By Used In Financing Activities | -560000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20250331 | Net Cash Provided By Used In Operating Activities | -9390000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20240331 | Other Nonoperating Income Expense | 106000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20250331 | Payments To Acquire Property Plant And Equipment | 5235000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20240331 | Proceeds From Derivative Instrument Financing Activities | 2378000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20250331 | Profit Loss | -29945000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0001823239-25-000063 | 20250331 | Research And Development Expense | 2498000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Nucleic Acid Production Segment; Consolidation Items= Operating Segments; | ||
| 0001823239-25-000063 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 6225000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Biologics Safety Testing Segment; Geographical= Asia Pacific; | ||
| 0001823239-25-000063 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 87000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Nucleic Acid Production Segment; Geographical= Latin And Central America; | ||
| 0001823239-25-000063 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 18100000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Biologics Safety Testing Segment; Consolidation Items= Operating Segments; | ||
| 0001823239-25-000063 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 7295000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Biologics Safety Testing Segment; Geographical= North America; | ||
| 0001823239-25-000063 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 28750000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Nucleic Acid Production Segment; | ||
| 0001823239-25-000063 | 20231231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 1191000.0000 | USD | 0 | us-gaap/2024 | Class Of Stock= Common Class B; Equity Components= Common Stock; | ||
| 0001823239-25-000063 | 20231231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 285737000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0001823239-25-000063 | 20240331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 1191000.0000 | USD | 0 | us-gaap/2024 | Class Of Stock= Common Class B; Equity Components= Common Stock; | ||
| 0001823239-25-000063 | 20240331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 134482000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001823239-25-000063 | 20240331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 366730000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Noncontrolling Interest; | ||
| 0001823239-25-000063 | 20240331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 273659000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0001823239-25-000063 | 20250331 | Stock Issued During Period Value New Issues | 20000.0000 | USD | 1 | us-gaap/2024 | Class Of Stock= Common Class A; Equity Components= Common Stock; | ||
| 0001823239-25-000063 | 20241231 | Accounts Payable Current | 11957000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20241231 | Accounts Receivable Net Current | 38520000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20240331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 5711000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Noncontrolling Interest; | ||
| 0001823239-25-000063 | 20240331 | Amortization Of Financing Costs | 740000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20250331 | Cash And Cash Equivalents At Carrying Value | 285053000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20250331 | Common Stock Shares Issued | 110684000.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Common Class B; | ||
| 0001823239-25-000063 | 20250331 | Common Stock Shares Outstanding | 110684000.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Common Class B; Equity Components= Common Stock; | ||
| 0001823239-25-000063 | 20240331 | Costs And Expenses | 83040000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20250331 | Deferred Income Tax Liabilities Net | 1974000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20250331 | Goodwill | 39950000.0000 | USD | 0 | us-gaap/2024 | Business Segments= Nucleic Acid Production Segment; | ||
| 0001823239-25-000063 | 20250331 | Goodwill Impairment Loss | 0.0000 | USD | 1 | us-gaap/2024 | Business Segments= Biologics Safety Testing Segment; | ||
| 0001823239-25-000063 | 20250331 | Goodwill Impairment Loss | 0.0000 | USD | 1 | us-gaap/2024 | Business Segments= Nucleic Acid Production Segment; Reporting Unit= Unimpaired Reporting Units; | ||
| 0001823239-25-000063 | 20240331 | Income Taxes Paid Net | 197000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20250331 | Increase Decrease In Accrued Liabilities | 1457000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20241231 | Inventory Net | 50082000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20250331 | Long Term Debt Current | 5440000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20241231 | Minority Interest | 251917000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20250331 | Minority Interest | 229659000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20250331 | Noncash Business Combination Contingent Consideration Arrangements Liability | 4800000.0000 | USD | 1 | 0001823239-25-000063 | |||
| 0001823239-25-000063 | 20250331 | Operating Income Loss | -49162000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20250331 | Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax | 574000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20241231 | Other Liabilities Noncurrent | 52455000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20240331 | Payments To Acquire Property Plant And Equipment | 5665000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20250331 | Prepaid Expense And Other Assets Current | 12963000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20240331 | Research And Development Expense | 5032000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20250331 | Research And Development Expense | 4888000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20250331 | Research And Development Expense | 585000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Biologics Safety Testing Segment; Consolidation Items= Operating Segments; | ||
| 0001823239-25-000063 | 20240331 | Restructuring Charges | -1212000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 64179000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 46016000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Nucleic Acid Production Segment; Consolidation Items= Operating Segments; | ||
| 0001823239-25-000063 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 21974000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Nucleic Acid Production Segment; Geographical= North America; | ||
| 0001823239-25-000063 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 29269000.0000 | USD | 1 | us-gaap/2024 | Geographical= North America; | ||
| 0001823239-25-000063 | 20240331 | Share Based Compensation | 12057000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20250331 | Stockholders Equity | 300614000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20231231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 128503000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001823239-25-000063 | 20240331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 1327000.0000 | USD | 0 | us-gaap/2024 | Class Of Stock= Common Class A; Equity Components= Common Stock; | ||
| 0001823239-25-000063 | 20250331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 1107000.0000 | USD | 0 | us-gaap/2024 | Class Of Stock= Common Class B; Equity Components= Common Stock; | ||
| 0001823239-25-000063 | 20240331 | Stock Issued During Period Shares New Issues | 427000.0000 | shares | 1 | us-gaap/2024 | Class Of Stock= Common Class A; Equity Components= Common Stock; | ||
| 0001823239-25-000063 | 20240331 | Stock Issued During Period Value New Issues | -1877000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001823239-25-000063 | 20250331 | Accounts Payable Current | 0.0000 | USD | 0 | us-gaap/2024 | Counterparty Name= M L S H1 And M L S H2; Related Party Transaction= Tax Receivable Agreement Payments; Related Party Transactions By Related Party= Related Party; | ||
| 0001823239-25-000063 | 20241231 | Accrued Liabilities Current | 36407000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20240331 | Accrued Receivable For Capital Expenditures To Be Reimbursed Under Government Contract | 2844000.0000 | USD | 1 | 0001823239-25-000063 | |||
| 0001823239-25-000063 | 20241231 | Accumulated Other Comprehensive Income Loss Net Of Tax | 0.0000 | USD | 0 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20241231 | Additional Paid In Capital | 181874000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20250331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 5872000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001823239-25-000063 | 20241231 | Assets Current | 429146000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20250331 | Assets Current | 376282000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20250331 | Capital Expenditures Incurred But Not Yet Paid | 1434000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20241231 | Common Stock Par Or Stated Value Per Share | 0.0100 | USD | 0 | us-gaap/2024 | Class Of Stock= Common Class B; | ||
| 0001823239-25-000063 | 20250331 | Common Stock Shares Authorized | 256856000.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Common Class B; | ||
| 0001823239-25-000063 | 20241231 | Common Stock Shares Issued | 110684000.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Common Class B; | ||
| 0001823239-25-000063 | 20250331 | Common Stock Shares Outstanding | 110684000.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Common Class B; | ||
| 0001823239-25-000063 | 20250331 | Common Stock Value | 1440000.0000 | USD | 0 | us-gaap/2024 | Class Of Stock= Common Class A; | ||
| 0001823239-25-000063 | 20250331 | Common Stock Value | 1107000.0000 | USD | 0 | us-gaap/2024 | Class Of Stock= Common Class B; | ||
| 0001823239-25-000063 | 20240331 | Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest | -10602000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20240331 | Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest | -22680000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20250331 | Contract With Customer Liability Current | 2756000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20250331 | Cost Of Revenue | 39125000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20250331 | Cost Of Revenue | 24822000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Nucleic Acid Production Segment; Consolidation Items= Operating Segments; | ||
| 0001823239-25-000063 | 20241231 | Derivative Assets Current | 1400000.0000 | USD | 0 | us-gaap/2024 | Derivative Instrument Risk= Interest Rate Cap; | ||
| 0001823239-25-000063 | 20250331 | Derivative Assets Current | 0.0000 | USD | 0 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20241231 | Finance Lease Liability Noncurrent | 31106000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20241231 | Goodwill | 39950000.0000 | USD | 0 | us-gaap/2024 | Business Segments= Nucleic Acid Production Segment; | ||
| 0001823239-25-000063 | 20250131 | Goodwill | 3436000.0000 | USD | 0 | us-gaap/2024 | Business Acquisition= Molecular Assemblies Inc; | ||
| 0001823239-25-000063 | 20250331 | Goodwill | 119928000.0000 | USD | 0 | us-gaap/2024 | Business Segments= Biologics Safety Testing Segment; | ||
| 0001823239-25-000063 | 20250331 | Income Taxes Paid Net | 139000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20240331 | Increase Decrease In Accrued Liabilities | -24116000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20250331 | Increase Decrease In Inventories | -449000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20250331 | Increase Decrease In Prepaid Deferred Expense And Other Assets | -2241000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20241231 | Intangible Assets Net Excluding Goodwill | 194957000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20250331 | Interest Expense Nonoperating | 6778000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20241231 | Liabilities And Stockholders Equity | 1008244000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20250331 | Liabilities And Stockholders Equity | 959751000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20240331 | Minority Interest Period Increase Decrease | 1510000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001823239-25-000063 | 20240331 | Net Income Loss Attributable To Noncontrolling Interest | -10602000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20250331 | Net Income Loss Attributable To Noncontrolling Interest | -22908000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20250331 | Operating Lease Right Of Use Asset Amortization Expense | 2187000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20241231 | Other Assets Noncurrent | 59789000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20250331 | Payments To Acquire Businesses Net Of Cash Acquired | 18628000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20240331 | Proceeds From Government Assistance Allocated To Property And Equipment | 1421000.0000 | USD | 1 | 0001823239-25-000063 | |||
| 0001823239-25-000063 | 20240331 | Profit Loss | -10602000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Noncontrolling Interest; | ||
| 0001823239-25-000063 | 20250331 | Profit Loss | -22908000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Noncontrolling Interest; | ||
| 0001823239-25-000063 | 20240331 | Repayments Of Long Term Debt | 1360000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20240331 | Research And Development Expense | 529000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Biologics Safety Testing Segment; Consolidation Items= Operating Segments; | ||
| 0001823239-25-000063 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 18163000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Biologics Safety Testing Segment; Consolidation Items= Operating Segments; | ||
| 0001823239-25-000063 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 0.0000 | USD | 1 | us-gaap/2024 | Consolidation Items= Intersegment Elimination; | ||
| 0001823239-25-000063 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 9365000.0000 | USD | 1 | us-gaap/2024 | Geographical= E M E A; | ||
| 0001823239-25-000063 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 4147000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Nucleic Acid Production Segment; Geographical= Asia Pacific; | ||
| 0001823239-25-000063 | 20241231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 577209000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20241231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 0.0000 | USD | 0 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0001823239-25-000063 | 20250331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 110946000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0001823239-25-000063 | 20240331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 12057000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20240331 | Amortization Of Intangible Assets | 6200000.0000 | USD | 1 | us-gaap/2024 | Income Statement Location= Cost Of Sales; | ||
| 0001823239-25-000063 | 20241231 | Assets | 1008244000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20240331 | Capital Expenditures Incurred But Not Yet Paid | 3162000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20250331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 530273000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20250331 | Commitments And Contingencies | USD | 0 | us-gaap/2024 | ||||
| 0001823239-25-000063 | 20241231 | Common Stock Shares Authorized | 500000000.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Common Class A; | ||
| 0001823239-25-000063 | 20250331 | Common Stock Shares Issued | 143958000.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Common Class A; | ||
| 0001823239-25-000063 | 20231231 | Common Stock Shares Outstanding | 119094000.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Common Class B; Equity Components= Common Stock; | ||
| 0001823239-25-000063 | 20240331 | Common Stock Shares Outstanding | 132655000.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Common Class A; Equity Components= Common Stock; | ||
| 0001823239-25-000063 | 20250331 | Common Stock Shares Outstanding | 143958000.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Common Class A; Equity Components= Common Stock; | ||
| 0001823239-25-000063 | 20241231 | Common Stock Value | 1420000.0000 | USD | 0 | us-gaap/2024 | Class Of Stock= Common Class A; | ||
| 0001823239-25-000063 | 20250331 | Cost Of Revenue | 2801000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Biologics Safety Testing Segment; Consolidation Items= Operating Segments; | ||
| 0001823239-25-000063 | 20241231 | Deferred Income Tax Liabilities Net | 11000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20250331 | Finance Lease Principal Payments | 183000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20240331 | Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -22409000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20240331 | Income Tax Expense Benefit | 271000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20250331 | Increase Decrease In Other Noncurrent Liabilities | -8490000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20250331 | Interest Paid Net | 6518000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20250331 | Investment Income Interest | 3225000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20250331 | Long Term Debt Noncurrent | 289499000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20250331 | Minority Interest Period Increase Decrease | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20240331 | Net Cash Provided By Used In Operating Activities | -8467000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20240331 | Net Income Loss | -12078000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20240331 | Noncash Or Part Noncash Acquisition Payables Assumed1 | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20250331 | Noncash Or Part Noncash Acquisition Payables Assumed1 | 2331000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20250331 | Other Assets Noncurrent | 57582000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20240331 | Other Noncash Income Expense | -223000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20250331 | Other Nonoperating Income Expense | 24000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20241231 | Prepaid Expense And Other Assets Current | 16770000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20250331 | Proceeds From Government Assistance Allocated To Property And Equipment | 734000.0000 | USD | 1 | 0001823239-25-000063 | |||
| 0001823239-25-000063 | 20250331 | Restructuring Charges | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20250331 | Retained Earnings Accumulated Deficit | 110946000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 7093000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Biologics Safety Testing Segment; Geographical= North America; | ||
| 0001823239-25-000063 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 14911000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Nucleic Acid Production Segment; Geographical= Asia Pacific; | ||
| 0001823239-25-000063 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 6410000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Biologics Safety Testing Segment; Geographical= Asia Pacific; | ||
| 0001823239-25-000063 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 46850000.0000 | USD | 1 | us-gaap/2024 | Consolidation Items= Operating Segments; | ||
| 0001823239-25-000063 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 6878000.0000 | USD | 1 | us-gaap/2024 | Geographical= E M E A; | ||
| 0001823239-25-000063 | 20250331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 186797000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001823239-25-000063 | 20250331 | Stock Issued During Period Value New Issues | -5060000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20250331 | Weighted Average Number Of Shares Outstanding Basic | 143425000.0000 | shares | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20240331 | Net Cash Provided By Used In Investing Activities | -4244000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20240331 | Payments To Acquire Businesses Net Of Cash Acquired | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20240331 | Increase Decrease In Accounts Receivable | -17883000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20250331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 10403000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20250331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 4531000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Noncontrolling Interest; | ||
| 0001823239-25-000063 | 20241231 | Commitments And Contingencies | USD | 0 | us-gaap/2024 | ||||
| 0001823239-25-000063 | 20241231 | Common Stock Shares Authorized | 256856000.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Common Class B; | ||
| 0001823239-25-000063 | 20241231 | Common Stock Shares Outstanding | 110684000.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Common Class B; | ||
| 0001823239-25-000063 | 20250331 | Common Stock Shares Outstanding | 143958000.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Common Class A; | ||
| 0001823239-25-000063 | 20250331 | Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest | -22658000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20250331 | Costs And Expenses | 96012000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20250331 | Earnings Per Share Basic | -0.2100 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20250331 | Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 73000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20241231 | Finance Lease Liability Current | 792000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20250228 | Goodwill | 8771000.0000 | USD | 0 | us-gaap/2024 | Business Acquisition= Officinae Bio; | ||
| 0001823239-25-000063 | 20240331 | Goodwill Impairment Loss | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20240331 | Increase Decrease In Contract With Customer Liability | -1150000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20240331 | Interest Expense Nonoperating | 10864000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20240331 | Interest Paid Net | 12140000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20250331 | Liabilities | 429478000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20250331 | Minority Interest Period Increase Decrease | 4131000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001823239-25-000063 | 20250331 | Other Liabilities Noncurrent | 43966000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20241231 | Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization | 164474000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20240331 | Research And Development Expense | 2463000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Nucleic Acid Production Segment; Consolidation Items= Operating Segments; | ||
| 0001823239-25-000063 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 18163000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Biologics Safety Testing Segment; | ||
| 0001823239-25-000063 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 4740000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Nucleic Acid Production Segment; Geographical= E M E A; | ||
| 0001823239-25-000063 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 46850000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 2594000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Nucleic Acid Production Segment; Geographical= E M E A; | ||
| 0001823239-25-000063 | 20250331 | Share Based Payment Arrangement Value Shares Withheld For Tax Withholding Obligation | -4732000.0000 | USD | 1 | 0001823239-25-000063 | |||
| 0001823239-25-000063 | 20241231 | Stockholders Equity | 325292000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20231231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 1322000.0000 | USD | 0 | us-gaap/2024 | Class Of Stock= Common Class A; Equity Components= Common Stock; | ||
| 0001823239-25-000063 | 20231231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 373131000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Noncontrolling Interest; | ||
| 0001823239-25-000063 | 20241231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 1420000.0000 | USD | 0 | us-gaap/2024 | Class Of Stock= Common Class A; Equity Components= Common Stock; | ||
| 0001823239-25-000063 | 20241231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 251917000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Noncontrolling Interest; | ||
| 0001823239-25-000063 | 20250331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 1440000.0000 | USD | 0 | us-gaap/2024 | Class Of Stock= Common Class A; Equity Components= Common Stock; | ||
| 0001823239-25-000063 | 20250331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 229659000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Noncontrolling Interest; | ||
| 0001823239-25-000063 | 20240331 | Stock Issued During Period Value New Issues | -1872000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20250331 | Stock Issued During Period Value New Issues | -5080000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001823239-25-000063 | 20240331 | Weighted Average Number Of Diluted Shares Outstanding | 132333000.0000 | shares | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20240331 | Weighted Average Number Of Shares Outstanding Basic | 132333000.0000 | shares | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20250331 | Net Income Loss | -29945000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20240331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 6346000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001823239-25-000063 | 20250331 | Amortization Of Intangible Assets | 7030000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20231231 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 574962000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20240331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 561691000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20250331 | Common Stock Par Or Stated Value Per Share | 0.0100 | USD | 0 | us-gaap/2024 | Class Of Stock= Common Class A; | ||
| 0001823239-25-000063 | 20231231 | Common Stock Shares Outstanding | 132228000.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Common Class A; Equity Components= Common Stock; | ||
| 0001823239-25-000063 | 20240331 | Common Stock Shares Outstanding | 119094000.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Common Class B; Equity Components= Common Stock; | ||
| 0001823239-25-000063 | 20240331 | Cost Of Revenue | 1754000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Biologics Safety Testing Segment; Consolidation Items= Operating Segments; | ||
| 0001823239-25-000063 | 20240331 | Earnings Per Share Basic | -0.0900 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20240331 | Finance Lease Principal Payments | 145000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20250331 | Goodwill | 159878000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20241231 | Long Term Debt Noncurrent | 290492000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20250331 | Minority Interest Period Increase Decrease | -4131000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Noncontrolling Interest; | ||
| 0001823239-25-000063 | 20240331 | Noncash Business Combination Contingent Consideration Arrangements Liability | 0.0000 | USD | 1 | 0001823239-25-000063 | |||
| 0001823239-25-000063 | 20240331 | Operating Lease Right Of Use Asset Amortization Expense | 2098000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20250331 | Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax | 324000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0001823239-25-000063 | 20250331 | Proceeds From Derivative Instrument Financing Activities | 1375000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20250331 | Profit Loss | -52853000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20250331 | Repayments Of Long Term Debt | 1360000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 26278000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Nucleic Acid Production Segment; Geographical= North America; | ||
| 0001823239-25-000063 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 21136000.0000 | USD | 1 | us-gaap/2024 | Geographical= Asia Pacific; | ||
| 0001823239-25-000063 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 307000.0000 | USD | 1 | us-gaap/2024 | Geographical= Latin And Central America; | ||
| 0001823239-25-000063 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 18100000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Biologics Safety Testing Segment; | ||
| 0001823239-25-000063 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 35000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Nucleic Acid Production Segment; Geographical= Latin And Central America; | ||
| 0001823239-25-000063 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 0.0000 | USD | 1 | us-gaap/2024 | Consolidation Items= Intersegment Elimination; | ||
| 0001823239-25-000063 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 10557000.0000 | USD | 1 | us-gaap/2024 | Geographical= Asia Pacific; | ||
| 0001823239-25-000063 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 146000.0000 | USD | 1 | us-gaap/2024 | Geographical= Latin And Central America; | ||
| 0001823239-25-000063 | 20240331 | Selling General And Administrative Expense | 40885000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20250331 | Selling General And Administrative Expense | 39564000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20250331 | Share Based Compensation | 10403000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20240331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 777389000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20241231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 1107000.0000 | USD | 0 | us-gaap/2024 | Class Of Stock= Common Class B; Equity Components= Common Stock; | ||
| 0001823239-25-000063 | 20241231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 181874000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001823239-25-000063 | 20250331 | Weighted Average Number Of Diluted Shares Outstanding | 143425000.0000 | shares | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20250331 | Accounts Payable Current | 9525000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20250331 | Accounts Receivable Net Current | 28493000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20250331 | Accrued Liabilities Current | 44603000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20250331 | Accumulated Other Comprehensive Income Loss Net Of Tax | 324000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20250331 | Additional Paid In Capital | 186797000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20250331 | Amortization Of Financing Costs | 461000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20250331 | Amortization Of Intangible Assets | 600000.0000 | USD | 1 | us-gaap/2024 | Income Statement Location= Selling General And Administrative Expenses; | ||
| 0001823239-25-000063 | 20250331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 285053000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20250331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | -37346000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20250331 | Common Stock Par Or Stated Value Per Share | 0.0100 | USD | 0 | us-gaap/2024 | Class Of Stock= Common Class B; | ||
| 0001823239-25-000063 | 20241231 | Common Stock Shares Issued | 141976000.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Common Class A; | ||
| 0001823239-25-000063 | 20250331 | Comprehensive Income Net Of Tax | -29621000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20250331 | Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest | -52279000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20240331 | Cost Of Revenue | 24624000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Nucleic Acid Production Segment; Consolidation Items= Operating Segments; | ||
| 0001823239-25-000063 | 20250331 | Depreciation | 5693000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20240331 | Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20250331 | Goodwill | 3400000.0000 | USD | 0 | us-gaap/2024 | Business Acquisition= Molecular Assemblies Inc; | ||
| 0001823239-25-000063 | 20250331 | Increase Decrease In Accounts Payable | -708000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20250331 | Increase Decrease In Contract With Customer Liability | 381000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20240331 | Increase Decrease In Other Noncurrent Liabilities | -1126000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20241231 | Liabilities | 431035000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20250331 | Liabilities Current | 63158000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20241231 | Long Term Debt Current | 5440000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20250331 | Net Cash Provided By Used In Financing Activities | -4900000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20250331 | Net Cash Provided By Used In Investing Activities | -23129000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20240331 | Operating Income Loss | -18861000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20240331 | Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20250331 | Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax | 250000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Noncontrolling Interest; | ||
| 0001823239-25-000063 | 20250331 | Other Noncash Income Expense | 236000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20240331 | Profit Loss | -12078000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0001823239-25-000063 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 4625000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Biologics Safety Testing Segment; Geographical= E M E A; | ||
| 0001823239-25-000063 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 111000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Biologics Safety Testing Segment; Geographical= Latin And Central America; | ||
| 0001823239-25-000063 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 28750000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Nucleic Acid Production Segment; Consolidation Items= Operating Segments; | ||
| 0001823239-25-000063 | 20231231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 789884000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20241231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 140891000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0001823239-25-000063 | 20240331 | Stock Issued During Period Value New Issues | 5000.0000 | USD | 1 | us-gaap/2024 | Class Of Stock= Common Class A; Equity Components= Common Stock; | ||
| 0001823239-25-000063 | 20250331 | Amortization Of Intangible Assets | 6400000.0000 | USD | 1 | us-gaap/2024 | Income Statement Location= Cost Of Sales; | ||
| 0001823239-25-000063 | 20241231 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 322399000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20240331 | Change In Unrealized Gain Loss On Fair Value Hedging Instruments1 | 1919000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20241231 | Common Stock Par Or Stated Value Per Share | 0.0100 | USD | 0 | us-gaap/2024 | Class Of Stock= Common Class A; | ||
| 0001823239-25-000063 | 20241231 | Common Stock Shares Outstanding | 141976000.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Common Class A; | ||
| 0001823239-25-000063 | 20241231 | Common Stock Shares Outstanding | 110684000.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Common Class B; Equity Components= Common Stock; | ||
| 0001823239-25-000063 | 20241231 | Common Stock Value | 1107000.0000 | USD | 0 | us-gaap/2024 | Class Of Stock= Common Class B; | ||
| 0001823239-25-000063 | 20240331 | Comprehensive Income Net Of Tax | -12078000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20240331 | Depreciation | 4786000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20250331 | Finance Lease Liability Current | 834000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20250331 | Finance Lease Liability Noncurrent | 30881000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20241231 | Goodwill | 119928000.0000 | USD | 0 | us-gaap/2024 | Business Segments= Biologics Safety Testing Segment; | ||
| 0001823239-25-000063 | 20250331 | Goodwill | 8800000.0000 | USD | 0 | us-gaap/2024 | Business Acquisition= Officinae Bio; | ||
| 0001823239-25-000063 | 20250331 | Goodwill Impairment Loss | 12400000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Nucleic Acid Production Segment; Reporting Unit= Tri Link; | ||
| 0001823239-25-000063 | 20250331 | Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -52691000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20250331 | Income Tax Expense Benefit | 162000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20240331 | Increase Decrease In Accounts Payable | -3682000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20250331 | Increase Decrease In Accounts Receivable | -10160000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20240331 | Increase Decrease In Inventories | -820000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20240331 | Increase Decrease In Prepaid Deferred Expense And Other Assets | -730000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20250331 | Intangible Assets Net Excluding Goodwill | 199581000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20241231 | Liabilities Current | 56971000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20250331 | Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization | 166428000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20241231 | Retained Earnings Accumulated Deficit | 140891000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001823239-25-000063 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 220000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Biologics Safety Testing Segment; Geographical= Latin And Central America; | ||
| 0001823239-25-000063 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 46016000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Nucleic Acid Production Segment; | ||
| 0001823239-25-000063 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 64179000.0000 | USD | 1 | us-gaap/2024 | Consolidation Items= Operating Segments; | ||
| 0001823239-25-000063 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 33371000.0000 | USD | 1 | us-gaap/2024 | Geographical= North America; | ||
| 0001823239-25-000063 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 4284000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Biologics Safety Testing Segment; Geographical= E M E A; | ||
| 0001823239-25-000063 | 20240331 | Share Based Payment Arrangement Value Shares Withheld For Tax Withholding Obligation | -1433000.0000 | USD | 1 | 0001823239-25-000063 | |||
| 0001823239-25-000063 | 20250331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 324000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0001823239-25-000063 | 20250331 | Stock Issued During Period Shares New Issues | 1982000.0000 | shares | 1 | us-gaap/2024 | Class Of Stock= Common Class A; Equity Components= Common Stock; |
| Field Name | Field Description |
|---|---|
| adsh | Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission. |
| tag | The unique identifier (name) for a tag in a specific taxonomy release. |
| version | For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined. |
| ddate | The end date for the data value, rounded to the nearest month end. |
| qtrs | The count of the number of quarters represented by the data value, rounded to the nearest whole number. “0” indicates it is a point-in-time value. |
| uom | The unit of measure for the value. |
| segments | Tags used to represent axis and member reporting. |
| coreg | If specified, indicates a specific co-registrant, the parent company, or other entity (e.g., guarantor). NULL indicates the consolidated entity. |
| value | The value. This is not scaled, it is as found in the Interactive Data file, but is limited to four digits to the right of the decimal point. |
| footnote | The text of any superscripted footnotes on the value, as shown on the statement page, truncated to 512 characters, or if there is no footnote, then this field will be blank. |
| tag | version | custom | abstract | datatype | iord | crdr | tlabel | doc |
|---|---|---|---|---|---|---|---|---|
| Increase Decrease In Accounts Receivable | us-gaap/2024 | 0 | 0 | monetary | D | C | Increase (Decrease) in Accounts Receivable | The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. |
| Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest | us-gaap/2024 | 0 | 0 | monetary | D | C | Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest | Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners. |
| Assets Current | us-gaap/2024 | 0 | 0 | monetary | I | D | Assets, Current | Amount of asset recognized for present right to economic benefit, classified as current. |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | us-gaap/2024 | 0 | 0 | monetary | I | D | Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents | Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. |
| Revenue From Contract With Customer Excluding Assessed Tax | us-gaap/2024 | 0 | 0 | monetary | D | C | Revenue from Contract with Customer, Excluding Assessed Tax | Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. |
| Payments To Acquire Businesses Net Of Cash Acquired | us-gaap/2024 | 0 | 0 | monetary | D | C | Payments to Acquire Businesses, Net of Cash Acquired | The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase. |
| Payments To Acquire Property Plant And Equipment | us-gaap/2024 | 0 | 0 | monetary | D | C | Payments to Acquire Property, Plant, and Equipment | The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. |
| Stockholders Equity Including Portion Attributable To Noncontrolling Interest | us-gaap/2024 | 0 | 0 | monetary | I | C | Equity, Including Portion Attributable to Noncontrolling Interest | Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity. |
| Accounts Receivable Net Current | us-gaap/2024 | 0 | 0 | monetary | I | D | Accounts Receivable, after Allowance for Credit Loss, Current | Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. |
| Comprehensive Income Net Of Tax | us-gaap/2024 | 0 | 0 | monetary | D | C | Comprehensive Income (Loss), Net of Tax, Attributable to Parent | Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. |
| Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest | us-gaap/2024 | 0 | 0 | monetary | D | D | Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest | Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners. |
| Finance Lease Liability Noncurrent | us-gaap/2024 | 0 | 0 | monetary | I | C | Finance Lease, Liability, Noncurrent | Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent. |
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | us-gaap/2024 | 0 | 0 | monetary | D | C | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. |
| Increase Decrease In Contract With Customer Liability | us-gaap/2024 | 0 | 0 | monetary | D | D | Increase (Decrease) in Contract with Customer, Liability | Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable. |
| Liabilities | us-gaap/2024 | 0 | 0 | monetary | I | C | Liabilities | Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. |
| Liabilities And Stockholders Equity | us-gaap/2024 | 0 | 0 | monetary | I | C | Liabilities and Equity | Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. |
| Minority Interest Period Increase Decrease | us-gaap/2024 | 0 | 0 | monetary | D | Noncontrolling Interest, Period Increase (Decrease) | Net Increase or Decrease in balance of noncontrolling interest in the subsidiary during the reporting period. | |
| Net Income Loss Attributable To Noncontrolling Interest | us-gaap/2024 | 0 | 0 | monetary | D | D | Net Income (Loss) Attributable to Noncontrolling Interest | Amount of Net Income (Loss) attributable to noncontrolling interest. |
| Retained Earnings Accumulated Deficit | us-gaap/2024 | 0 | 0 | monetary | I | C | Retained Earnings (Accumulated Deficit) | Amount of accumulated undistributed earnings (deficit). |
| Accrued Receivable For Capital Expenditures To Be Reimbursed Under Government Contract | 0001823239-25-000063 | 1 | 0 | monetary | D | C | Accrued Receivable For Capital Expenditures To Be Reimbursed Under Government Contract | Accrued Receivable For Capital Expenditures To Be Reimbursed Under Government Contract |
| Additional Paid In Capital | us-gaap/2024 | 0 | 0 | monetary | I | C | Additional Paid in Capital | Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. |
| Common Stock Par Or Stated Value Per Share | us-gaap/2024 | 0 | 0 | perShare | I | Common Stock, Par or Stated Value Per Share | Face amount or stated value per share of common stock. | |
| Common Stock Shares Outstanding | us-gaap/2024 | 0 | 0 | shares | I | Common Stock, Shares, Outstanding | Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. | |
| Income Tax Expense Benefit | us-gaap/2024 | 0 | 0 | monetary | D | D | Income Tax Expense (Benefit) | Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. |
| Net Income Loss | us-gaap/2024 | 0 | 0 | monetary | D | C | Net Income (Loss) Attributable to Parent | The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. |
| Stockholders Equity | us-gaap/2024 | 0 | 0 | monetary | I | C | Equity, Attributable to Parent | Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. |
| Weighted Average Number Of Diluted Shares Outstanding | us-gaap/2024 | 0 | 0 | shares | D | Weighted Average Number of Shares Outstanding, Diluted | The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. | |
| Accumulated Other Comprehensive Income Loss Net Of Tax | us-gaap/2024 | 0 | 0 | monetary | I | C | Accumulated Other Comprehensive Income (Loss), Net of Tax | Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. |
| Noncash Business Combination Contingent Consideration Arrangements Liability | 0001823239-25-000063 | 1 | 0 | monetary | D | D | Noncash Business Combination, Contingent Consideration Arrangements, Liability | Noncash Business Combination, Contingent Consideration Arrangements, Liability |
| Assets | us-gaap/2024 | 0 | 0 | monetary | I | D | Assets | Amount of asset recognized for present right to economic benefit. |
| Common Stock Shares Issued | us-gaap/2024 | 0 | 0 | shares | I | Common Stock, Shares, Issued | Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. | |
| Earnings Per Share Diluted | us-gaap/2024 | 0 | 0 | perShare | D | Earnings Per Share, Diluted | The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. | |
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | us-gaap/2024 | 0 | 0 | monetary | D | D | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations | Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. |
| Costs And Expenses | us-gaap/2024 | 0 | 0 | monetary | D | D | Costs and Expenses | Total costs of sales and operating expenses for the period. |
| Other Assets Noncurrent | us-gaap/2024 | 0 | 0 | monetary | I | D | Other Assets, Noncurrent | Amount of noncurrent assets classified as other. |
| Proceeds From Government Assistance Allocated To Property And Equipment | 0001823239-25-000063 | 1 | 0 | monetary | D | D | Proceeds From Government Assistance Allocated To Property And Equipment | Proceeds From Government Assistance Allocated To Property And Equipment |
| Share Based Payment Arrangement Value Shares Withheld For Tax Withholding Obligation | 0001823239-25-000063 | 1 | 0 | monetary | D | D | Share-Based Payment Arrangement, Value, Shares Withheld For Tax Withholding Obligation | Share-Based Payment Arrangement, Value, Shares Withheld For Tax Withholding Obligation |
| Accrued Liabilities Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Accrued Liabilities, Current | Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). |
| Change In Unrealized Gain Loss On Fair Value Hedging Instruments1 | us-gaap/2024 | 0 | 0 | monetary | D | C | Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments | Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement. |
| Cost Of Revenue | us-gaap/2024 | 0 | 0 | monetary | D | D | Cost of Revenue | The aggregate cost of goods produced and sold and services rendered during the reporting period. |
| Finance Lease Principal Payments | us-gaap/2024 | 0 | 0 | monetary | D | C | Finance Lease, Principal Payments | Amount of cash outflow for principal payment on finance lease. |
| Goodwill Impairment Loss | us-gaap/2024 | 0 | 0 | monetary | D | D | Goodwill, Impairment Loss | Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. |
| Interest Expense Nonoperating | us-gaap/2024 | 0 | 0 | monetary | D | D | Interest Expense, Nonoperating | Amount of interest expense classified as nonoperating. |
| Liabilities Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Liabilities, Current | Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. |
| Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax | us-gaap/2024 | 0 | 0 | monetary | D | C | Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax | Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature. |
| Repayments Of Long Term Debt | us-gaap/2024 | 0 | 0 | monetary | D | C | Repayments of Long-Term Debt | The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer. |
| Restructuring Charges | us-gaap/2024 | 0 | 0 | monetary | D | D | Restructuring Charges | Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation. |
| Selling General And Administrative Expense | us-gaap/2024 | 0 | 0 | monetary | D | D | Selling, General and Administrative Expense | The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. |
| Share Based Compensation | us-gaap/2024 | 0 | 0 | monetary | D | D | Share-Based Payment Arrangement, Noncash Expense | Amount of noncash expense for share-based payment arrangement. |
| Cash And Cash Equivalents At Carrying Value | us-gaap/2024 | 0 | 0 | monetary | I | D | Cash and Cash Equivalents, at Carrying Value | Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. |
| Income Taxes Paid Net | us-gaap/2024 | 0 | 0 | monetary | D | C | Income Taxes Paid, Net | Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax. |
| Increase Decrease In Inventories | us-gaap/2024 | 0 | 0 | monetary | D | C | Increase (Decrease) in Inventories | The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities. |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | us-gaap/2024 | 0 | 0 | monetary | D | C | Increase (Decrease) in Prepaid Expense and Other Assets | Amount of increase (decrease) in prepaid expenses, and assets classified as other. |
| Other Noncash Income Expense | us-gaap/2024 | 0 | 0 | monetary | D | C | Other Noncash Income (Expense) | Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other. |
| Profit Loss | us-gaap/2024 | 0 | 0 | monetary | D | C | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. |
| Derivative Assets Current | us-gaap/2024 | 0 | 0 | monetary | I | D | Derivative Asset, Current | Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset. |
| Goodwill | us-gaap/2024 | 0 | 0 | monetary | I | D | Goodwill | Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. |
| Intangible Assets Net Excluding Goodwill | us-gaap/2024 | 0 | 0 | monetary | I | D | Intangible Assets, Net (Excluding Goodwill) | Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. |
| Net Cash Provided By Used In Operating Activities | us-gaap/2024 | 0 | 0 | monetary | D | Net Cash Provided by (Used in) Operating Activities | Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. | |
| Noncash Or Part Noncash Acquisition Payables Assumed1 | us-gaap/2024 | 0 | 0 | monetary | D | C | Noncash or Part Noncash Acquisition, Payables Assumed | The amount of payables that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. |
| Operating Income Loss | us-gaap/2024 | 0 | 0 | monetary | D | C | Operating Income (Loss) | The net result for the period of deducting operating expenses from operating revenues. |
| Other Liabilities Noncurrent | us-gaap/2024 | 0 | 0 | monetary | I | C | Other Liabilities, Noncurrent | Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer. |
| Prepaid Expense And Other Assets Current | us-gaap/2024 | 0 | 0 | monetary | I | D | Prepaid Expense and Other Assets, Current | Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. |
| Amortization Of Financing Costs | us-gaap/2024 | 0 | 0 | monetary | D | D | Amortization of Debt Issuance Costs | Amount of amortization expense attributable to debt issuance costs. |
| Capital Expenditures Incurred But Not Yet Paid | us-gaap/2024 | 0 | 0 | monetary | D | C | Capital Expenditures Incurred but Not yet Paid | Future cash outflow to pay for purchases of fixed assets that have occurred. |
| Research And Development Expense | us-gaap/2024 | 0 | 0 | monetary | D | D | Research and Development Expense | Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. |
| Common Stock Value | us-gaap/2024 | 0 | 0 | monetary | I | C | Common Stock, Value, Issued | Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. |
| Inventory Net | us-gaap/2024 | 0 | 0 | monetary | I | D | Inventory, Net | Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. |
| Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization | us-gaap/2024 | 0 | 0 | monetary | I | D | Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization | Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset. |
| Accounts Payable Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Accounts Payable, Current | Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). |
| Stock Issued During Period Shares New Issues | us-gaap/2024 | 0 | 0 | shares | D | Stock Issued During Period, Shares, New Issues | Number of new stock issued during the period. | |
| Amortization Of Intangible Assets | us-gaap/2024 | 0 | 0 | monetary | D | D | Amortization of Intangible Assets | The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | us-gaap/2024 | 0 | 0 | monetary | D | D | Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. |
| Commitments And Contingencies | us-gaap/2024 | 0 | 0 | monetary | I | C | Commitments and Contingencies | Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. |
| Common Stock Shares Authorized | us-gaap/2024 | 0 | 0 | shares | I | Common Stock, Shares Authorized | The maximum number of common shares permitted to be issued by an entity's charter and bylaws. | |
| Deferred Income Tax Liabilities Net | us-gaap/2024 | 0 | 0 | monetary | I | C | Deferred Income Tax Liabilities, Net | Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting. |
| Increase Decrease In Accounts Payable | us-gaap/2024 | 0 | 0 | monetary | D | D | Increase (Decrease) in Accounts Payable | The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. |
| Interest Paid Net | us-gaap/2024 | 0 | 0 | monetary | D | C | Interest Paid, Excluding Capitalized Interest, Operating Activities | Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount. |
| Net Cash Provided By Used In Financing Activities | us-gaap/2024 | 0 | 0 | monetary | D | D | Net Cash Provided by (Used in) Financing Activities | Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. |
| Operating Lease Right Of Use Asset Amortization Expense | us-gaap/2024 | 0 | 0 | monetary | D | D | Operating Lease, Right-of-Use Asset, Periodic Reduction | Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease. |
| Proceeds From Derivative Instrument Financing Activities | us-gaap/2024 | 0 | 0 | monetary | D | D | Proceeds from Derivative Instrument, Financing Activities | The cash inflow provided by derivative instruments during the period, which are classified as financing activities, excluding those designated as hedging instruments. |
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | us-gaap/2024 | 0 | 0 | monetary | D | C | APIC, Share-Based Payment Arrangement, Increase for Cost Recognition | Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. |
| Contract With Customer Liability Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Contract with Customer, Liability, Current | Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current. |
| Depreciation | us-gaap/2024 | 0 | 0 | monetary | D | D | Depreciation | The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. |
| Earnings Per Share Basic | us-gaap/2024 | 0 | 0 | perShare | D | Earnings Per Share, Basic | The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. | |
| Finance Lease Liability Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Finance Lease, Liability, Current | Present value of lessee's discounted obligation for lease payments from finance lease, classified as current. |
| Investment Income Interest | us-gaap/2024 | 0 | 0 | monetary | D | C | Investment Income, Interest | Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities. |
| Net Cash Provided By Used In Investing Activities | us-gaap/2024 | 0 | 0 | monetary | D | D | Net Cash Provided by (Used in) Investing Activities | Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. |
| Other Nonoperating Income Expense | us-gaap/2024 | 0 | 0 | monetary | D | C | Other Nonoperating Income (Expense) | Amount of income (expense) related to nonoperating activities, classified as other. |
| Stock Issued During Period Value New Issues | us-gaap/2024 | 0 | 0 | monetary | D | C | Stock Issued During Period, Value, New Issues | Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. |
| Increase Decrease In Accrued Liabilities | us-gaap/2024 | 0 | 0 | monetary | D | D | Increase (Decrease) in Accrued Liabilities | The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid. |
| Increase Decrease In Other Noncurrent Liabilities | us-gaap/2024 | 0 | 0 | monetary | D | D | Increase (Decrease) in Other Noncurrent Liabilities | Amount of increase (decrease) in noncurrent operating liabilities classified as other. |
| Long Term Debt Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Long-Term Debt, Current Maturities | Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation. |
| Long Term Debt Noncurrent | us-gaap/2024 | 0 | 0 | monetary | I | C | Long-Term Debt, Excluding Current Maturities | Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation. |
| Minority Interest | us-gaap/2024 | 0 | 0 | monetary | I | C | Equity, Attributable to Noncontrolling Interest | Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity. |
| Weighted Average Number Of Shares Outstanding Basic | us-gaap/2024 | 0 | 0 | shares | D | Weighted Average Number of Shares Outstanding, Basic | Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. |
| Field Name | Field Description |
|---|---|
| tag | The unique identifier (name) for a tag in a specific taxonomy release. |
| version | For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined. |
| custom | 1 if tag is custom (version=adsh), 0 if it is standard. Note: This flag is technically redundant with the version and adsh columns. |
| abstract | 1 if the tag is not used to represent a numeric fact. |
| datatype | If abstract=1, then NULL, otherwise the data type (e.g., monetary) for the tag. |
| iord | If abstract=1, then NULL; otherwise, “I” if the value is a point-in time, or “D” if the value is a duration. |
| crdr | If datatype = monetary, then the tag’s natural accounting balance (debit or credit); if not defined, then NULL. |
| tlabel | If a standard tag, then the label text provided by the taxonomy, otherwise the text provided by the filer. A tag which had neither would have a NULL value here. |
| doc | The detailed definition for the tag. If a standard tag, then the text provided by the taxonomy, otherwise the text assigned by the filer. Some tags have neither, and this field is NULL. |
| adsh | report | line | stmt | inpth | rfile | tag | version | plabel | negating |
|---|---|---|---|---|---|---|---|---|---|
| 0001823239-25-000063 | 2 | 9 | BS | 0 | H | Cash And Cash Equivalents At Carrying Value | us-gaap/2024 | Cash and cash equivalents | 0 |
| 0001823239-25-000063 | 2 | 10 | BS | 0 | H | Accounts Receivable Net Current | us-gaap/2024 | Accounts receivable, net | 0 |
| 0001823239-25-000063 | 2 | 11 | BS | 0 | H | Inventory Net | us-gaap/2024 | Inventory | 0 |
| 0001823239-25-000063 | 2 | 12 | BS | 0 | H | Prepaid Expense And Other Assets Current | us-gaap/2024 | Prepaid expenses and other current assets | 0 |
| 0001823239-25-000063 | 2 | 13 | BS | 0 | H | Derivative Assets Current | us-gaap/2024 | Interest rate cap | 0 |
| 0001823239-25-000063 | 2 | 14 | BS | 0 | H | Assets Current | us-gaap/2024 | Total current assets | 0 |
| 0001823239-25-000063 | 2 | 15 | BS | 0 | H | Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization | us-gaap/2024 | Property and equipment, net | 0 |
| 0001823239-25-000063 | 2 | 16 | BS | 0 | H | Goodwill | us-gaap/2024 | Goodwill | 0 |
| 0001823239-25-000063 | 2 | 17 | BS | 0 | H | Intangible Assets Net Excluding Goodwill | us-gaap/2024 | Intangible assets, net | 0 |
| 0001823239-25-000063 | 2 | 18 | BS | 0 | H | Other Assets Noncurrent | us-gaap/2024 | Other assets | 0 |
| 0001823239-25-000063 | 2 | 19 | BS | 0 | H | Assets | us-gaap/2024 | Total assets | 0 |
| 0001823239-25-000063 | 2 | 22 | BS | 0 | H | Accounts Payable Current | us-gaap/2024 | Accounts payable | 0 |
| 0001823239-25-000063 | 2 | 23 | BS | 0 | H | Accrued Liabilities Current | us-gaap/2024 | Accrued expenses and other current liabilities | 0 |
| 0001823239-25-000063 | 2 | 24 | BS | 0 | H | Contract With Customer Liability Current | us-gaap/2024 | Deferred revenue | 0 |
| 0001823239-25-000063 | 2 | 25 | BS | 0 | H | Long Term Debt Current | us-gaap/2024 | Current portion of long-term debt | 0 |
| 0001823239-25-000063 | 2 | 26 | BS | 0 | H | Finance Lease Liability Current | us-gaap/2024 | Current portion of finance lease liabilities | 0 |
| 0001823239-25-000063 | 2 | 27 | BS | 0 | H | Liabilities Current | us-gaap/2024 | Total current liabilities | 0 |
| 0001823239-25-000063 | 2 | 28 | BS | 0 | H | Long Term Debt Noncurrent | us-gaap/2024 | Long-term debt, less current portion | 0 |
| 0001823239-25-000063 | 2 | 29 | BS | 0 | H | Finance Lease Liability Noncurrent | us-gaap/2024 | Finance lease liabilities, less current portion | 0 |
| 0001823239-25-000063 | 2 | 30 | BS | 0 | H | Deferred Income Tax Liabilities Net | us-gaap/2024 | Deferred tax liabilities | 0 |
| 0001823239-25-000063 | 2 | 31 | BS | 0 | H | Other Liabilities Noncurrent | us-gaap/2024 | Other long-term liabilities | 0 |
| 0001823239-25-000063 | 2 | 32 | BS | 0 | H | Liabilities | us-gaap/2024 | Total liabilities | 0 |
| 0001823239-25-000063 | 2 | 33 | BS | 0 | H | Commitments And Contingencies | us-gaap/2024 | Commitments and contingencies (Note 7) | 0 |
| 0001823239-25-000063 | 2 | 35 | BS | 0 | H | Common Stock Value | us-gaap/2024 | Common stock | 0 |
| 0001823239-25-000063 | 2 | 36 | BS | 0 | H | Additional Paid In Capital | us-gaap/2024 | Additional paid-in capital | 0 |
| 0001823239-25-000063 | 2 | 37 | BS | 0 | H | Retained Earnings Accumulated Deficit | us-gaap/2024 | Retained earnings | 0 |
| 0001823239-25-000063 | 2 | 38 | BS | 0 | H | Accumulated Other Comprehensive Income Loss Net Of Tax | us-gaap/2024 | Accumulated other comprehensive income | 0 |
| 0001823239-25-000063 | 2 | 39 | BS | 0 | H | Stockholders Equity | us-gaap/2024 | Total stockholders equity attributable to Maravai LifeSciences Holdings, Inc. | 0 |
| 0001823239-25-000063 | 2 | 40 | BS | 0 | H | Minority Interest | us-gaap/2024 | Non-controlling interest | 0 |
| 0001823239-25-000063 | 2 | 41 | BS | 0 | H | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | us-gaap/2024 | Total stockholders equity | 0 |
| 0001823239-25-000063 | 2 | 42 | BS | 0 | H | Liabilities And Stockholders Equity | us-gaap/2024 | Total liabilities and stockholders equity | 0 |
| 0001823239-25-000063 | 3 | 7 | BS | 1 | H | Common Stock Par Or Stated Value Per Share | us-gaap/2024 | Common stock, par value (in usd per share) | 0 |
| 0001823239-25-000063 | 3 | 8 | BS | 1 | H | Common Stock Shares Authorized | us-gaap/2024 | Common stock, shares authorized (in shares) | 0 |
| 0001823239-25-000063 | 3 | 9 | BS | 1 | H | Common Stock Shares Issued | us-gaap/2024 | Common stock, shares issued (in shares) | 0 |
| 0001823239-25-000063 | 3 | 10 | BS | 1 | H | Common Stock Shares Outstanding | us-gaap/2024 | Common stock, shares outstanding (in shares) | 0 |
| 0001823239-25-000063 | 4 | 1 | IS | 0 | H | Revenue From Contract With Customer Excluding Assessed Tax | us-gaap/2024 | Revenue | 0 |
| 0001823239-25-000063 | 4 | 3 | IS | 0 | H | Cost Of Revenue | us-gaap/2024 | Cost of revenue | 0 |
| 0001823239-25-000063 | 4 | 4 | IS | 0 | H | Selling General And Administrative Expense | us-gaap/2024 | Selling, general and administrative | 0 |
| 0001823239-25-000063 | 4 | 5 | IS | 0 | H | Research And Development Expense | us-gaap/2024 | Research and development | 0 |
| 0001823239-25-000063 | 4 | 6 | IS | 0 | H | Goodwill Impairment Loss | us-gaap/2024 | Goodwill impairment | 0 |
| 0001823239-25-000063 | 4 | 7 | IS | 0 | H | Restructuring Charges | us-gaap/2024 | Restructuring | 0 |
| 0001823239-25-000063 | 4 | 8 | IS | 0 | H | Costs And Expenses | us-gaap/2024 | Total operating expenses | 0 |
| 0001823239-25-000063 | 4 | 9 | IS | 0 | H | Operating Income Loss | us-gaap/2024 | Loss from operations | 0 |
| 0001823239-25-000063 | 4 | 11 | IS | 0 | H | Interest Expense Nonoperating | us-gaap/2024 | Interest expense | 1 |
| 0001823239-25-000063 | 4 | 12 | IS | 0 | H | Investment Income Interest | us-gaap/2024 | Interest income | 0 |
| 0001823239-25-000063 | 4 | 13 | IS | 0 | H | Other Nonoperating Income Expense | us-gaap/2024 | Other income | 0 |
| 0001823239-25-000063 | 4 | 14 | IS | 0 | H | Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | us-gaap/2024 | Loss before income taxes | 0 |
| 0001823239-25-000063 | 4 | 15 | IS | 0 | H | Income Tax Expense Benefit | us-gaap/2024 | Income tax expense | 0 |
| 0001823239-25-000063 | 4 | 16 | IS | 0 | H | Profit Loss | us-gaap/2024 | Net loss | 0 |
| 0001823239-25-000063 | 4 | 17 | IS | 0 | H | Net Income Loss Attributable To Noncontrolling Interest | us-gaap/2024 | Net loss attributable to non-controlling interests | 0 |
| 0001823239-25-000063 | 4 | 18 | IS | 0 | H | Net Income Loss | us-gaap/2024 | Net loss attributable to Maravai LifeSciences Holdings, Inc. | 0 |
| 0001823239-25-000063 | 4 | 19 | IS | 0 | H | Earnings Per Share Basic | us-gaap/2024 | Net loss per Class A common share attributable to Maravai LifeSciences Holdings, Inc., basic (in usd per share) | 0 |
| 0001823239-25-000063 | 4 | 20 | IS | 0 | H | Earnings Per Share Diluted | us-gaap/2024 | Net loss per Class A common share attributable to Maravai LifeSciences Holdings, Inc., diluted (in usd per share) | 0 |
| 0001823239-25-000063 | 4 | 21 | IS | 0 | H | Weighted Average Number Of Shares Outstanding Basic | us-gaap/2024 | Weighted average number of Class A common shares outstanding, basic (in shares) | 0 |
| 0001823239-25-000063 | 4 | 22 | IS | 0 | H | Weighted Average Number Of Diluted Shares Outstanding | us-gaap/2024 | Weighted average number of Class A common shares outstanding, diluted (in shares) | 0 |
| 0001823239-25-000063 | 5 | 1 | CI | 0 | H | Profit Loss | us-gaap/2024 | Net loss | 0 |
| 0001823239-25-000063 | 5 | 3 | CI | 0 | H | Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax | us-gaap/2024 | Foreign currency translation adjustments | 0 |
| 0001823239-25-000063 | 5 | 4 | CI | 0 | H | Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest | us-gaap/2024 | Total other comprehensive loss | 0 |
| 0001823239-25-000063 | 5 | 5 | CI | 0 | H | Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest | us-gaap/2024 | Comprehensive loss attributable to non-controlling interests | 0 |
| 0001823239-25-000063 | 5 | 6 | CI | 0 | H | Comprehensive Income Net Of Tax | us-gaap/2024 | Total comprehensive loss attributable to Maravai LifeSciences Holdings, Inc. | 0 |
| 0001823239-25-000063 | 6 | 15 | EQ | 0 | H | Common Stock Shares Outstanding | us-gaap/2024 | Beginning balance (in shares) | 0 |
| 0001823239-25-000063 | 6 | 16 | EQ | 0 | H | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | us-gaap/2024 | Beginning balance | 0 |
| 0001823239-25-000063 | 6 | 17 | EQ | 0 | H | Stock Issued During Period Shares New Issues | us-gaap/2024 | Issuance of Class A common stock under employee equity plans, net of shares withheld for employee taxes (in shares) | 0 |
| 0001823239-25-000063 | 6 | 18 | EQ | 0 | H | Stock Issued During Period Value New Issues | us-gaap/2024 | Issuance of Class A common stock under employee equity plans, net of shares withheld for employee taxes | 0 |
| 0001823239-25-000063 | 6 | 19 | EQ | 0 | H | Minority Interest Period Increase Decrease | us-gaap/2024 | Non-controlling interest adjustment for changes in proportionate ownership in Topco LLC | 0 |
| 0001823239-25-000063 | 6 | 20 | EQ | 0 | H | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | us-gaap/2024 | Stock-based compensation | 0 |
| 0001823239-25-000063 | 6 | 21 | EQ | 0 | H | Profit Loss | us-gaap/2024 | Net loss | 0 |
| 0001823239-25-000063 | 6 | 22 | EQ | 0 | H | Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax | us-gaap/2024 | Foreign currency translation adjustments | 0 |
| 0001823239-25-000063 | 6 | 23 | EQ | 0 | H | Common Stock Shares Outstanding | us-gaap/2024 | Ending balance (in shares) | 0 |
| 0001823239-25-000063 | 6 | 24 | EQ | 0 | H | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | us-gaap/2024 | Ending balance | 0 |
| 0001823239-25-000063 | 7 | 2 | CF | 0 | H | Profit Loss | us-gaap/2024 | Net loss | 0 |
| 0001823239-25-000063 | 7 | 4 | CF | 0 | H | Depreciation | us-gaap/2024 | Depreciation | 0 |
| 0001823239-25-000063 | 7 | 5 | CF | 0 | H | Amortization Of Intangible Assets | us-gaap/2024 | Amortization of intangible assets | 0 |
| 0001823239-25-000063 | 7 | 6 | CF | 0 | H | Operating Lease Right Of Use Asset Amortization Expense | us-gaap/2024 | Amortization of operating lease right-of-use assets | 0 |
| 0001823239-25-000063 | 7 | 7 | CF | 0 | H | Amortization Of Financing Costs | us-gaap/2024 | Amortization of deferred financing costs | 0 |
| 0001823239-25-000063 | 7 | 8 | CF | 0 | H | Share Based Compensation | us-gaap/2024 | Stock-based compensation expense | 0 |
| 0001823239-25-000063 | 7 | 9 | CF | 0 | H | Goodwill Impairment Loss | us-gaap/2024 | Goodwill impairment | 0 |
| 0001823239-25-000063 | 7 | 10 | CF | 0 | H | Change In Unrealized Gain Loss On Fair Value Hedging Instruments1 | us-gaap/2024 | Change in fair value of derivative instruments | 1 |
| 0001823239-25-000063 | 7 | 11 | CF | 0 | H | Other Noncash Income Expense | us-gaap/2024 | Other | 1 |
| 0001823239-25-000063 | 7 | 13 | CF | 0 | H | Increase Decrease In Accounts Receivable | us-gaap/2024 | Accounts receivable | 1 |
| 0001823239-25-000063 | 7 | 14 | CF | 0 | H | Increase Decrease In Inventories | us-gaap/2024 | Inventory | 1 |
| 0001823239-25-000063 | 7 | 15 | CF | 0 | H | Increase Decrease In Prepaid Deferred Expense And Other Assets | us-gaap/2024 | Prepaid expenses and other current assets | 1 |
| 0001823239-25-000063 | 7 | 16 | CF | 0 | H | Increase Decrease In Accounts Payable | us-gaap/2024 | Accounts payable | 0 |
| 0001823239-25-000063 | 7 | 17 | CF | 0 | H | Increase Decrease In Accrued Liabilities | us-gaap/2024 | Accrued expenses and other current liabilities | 0 |
| 0001823239-25-000063 | 7 | 18 | CF | 0 | H | Increase Decrease In Contract With Customer Liability | us-gaap/2024 | Deferred revenue | 0 |
| 0001823239-25-000063 | 7 | 19 | CF | 0 | H | Increase Decrease In Other Noncurrent Liabilities | us-gaap/2024 | Other long-term liabilities | 0 |
| 0001823239-25-000063 | 7 | 20 | CF | 0 | H | Net Cash Provided By Used In Operating Activities | us-gaap/2024 | Net cash used in operating activities | 0 |
| 0001823239-25-000063 | 7 | 22 | CF | 0 | H | Payments To Acquire Businesses Net Of Cash Acquired | us-gaap/2024 | Cash paid for acquisitions of a business, net of cash acquired | 1 |
| 0001823239-25-000063 | 7 | 23 | CF | 0 | H | Payments To Acquire Property Plant And Equipment | us-gaap/2024 | Purchases of property and equipment | 1 |
| 0001823239-25-000063 | 7 | 24 | CF | 0 | H | Proceeds From Government Assistance Allocated To Property And Equipment | 0001823239-25-000063 | Proceeds from government assistance allocated to property and equipment | 0 |
| 0001823239-25-000063 | 7 | 25 | CF | 0 | H | Net Cash Provided By Used In Investing Activities | us-gaap/2024 | Net cash used in investing activities | 0 |
| 0001823239-25-000063 | 7 | 27 | CF | 0 | H | Repayments Of Long Term Debt | us-gaap/2024 | Principal repayments of long-term debt | 1 |
| 0001823239-25-000063 | 7 | 28 | CF | 0 | H | Finance Lease Principal Payments | us-gaap/2024 | Payments of finance lease liabilities | 1 |
| 0001823239-25-000063 | 7 | 29 | CF | 0 | H | Proceeds From Derivative Instrument Financing Activities | us-gaap/2024 | Proceeds from interest rate cap agreement | 0 |
| 0001823239-25-000063 | 7 | 30 | CF | 0 | H | Share Based Payment Arrangement Value Shares Withheld For Tax Withholding Obligation | 0001823239-25-000063 | Taxes paid for shares withheld under employee equity plans, net of proceeds from issuance of Class A common stock | 0 |
| 0001823239-25-000063 | 7 | 31 | CF | 0 | H | Net Cash Provided By Used In Financing Activities | us-gaap/2024 | Net cash used in financing activities | 0 |
| 0001823239-25-000063 | 7 | 32 | CF | 0 | H | Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | us-gaap/2024 | Effects of exchange rate changes on cash and cash equivalents | 0 |
| 0001823239-25-000063 | 7 | 33 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | us-gaap/2024 | Net decrease in cash and cash equivalents | 0 |
| 0001823239-25-000063 | 7 | 34 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | us-gaap/2024 | Cash and cash equivalents, beginning of period | 0 |
| 0001823239-25-000063 | 7 | 35 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | us-gaap/2024 | Cash and cash equivalents, end of period | 0 |
| 0001823239-25-000063 | 7 | 37 | CF | 0 | H | Interest Paid Net | us-gaap/2024 | Cash paid for interest | 0 |
| 0001823239-25-000063 | 7 | 38 | CF | 0 | H | Income Taxes Paid Net | us-gaap/2024 | Cash paid for income taxes, net | 0 |
| 0001823239-25-000063 | 7 | 40 | CF | 0 | H | Capital Expenditures Incurred But Not Yet Paid | us-gaap/2024 | Property and equipment included in accounts payable and accrued expenses | 0 |
| 0001823239-25-000063 | 7 | 41 | CF | 0 | H | Accrued Receivable For Capital Expenditures To Be Reimbursed Under Government Contract | 0001823239-25-000063 | Accrued receivable for capital expenditures to be reimbursed under a government contract | 0 |
| 0001823239-25-000063 | 7 | 42 | CF | 0 | H | Noncash Business Combination Contingent Consideration Arrangements Liability | 0001823239-25-000063 | Fair value of contingent consideration liability recorded in connection with acquisition of a business | 0 |
| 0001823239-25-000063 | 7 | 43 | CF | 0 | H | Noncash Or Part Noncash Acquisition Payables Assumed1 | us-gaap/2024 | Accrued consideration payable recorded in connection with acquisitions of a business | 0 |
| Field Name | Field Description |
|---|---|
| adsh | Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission. |
| report | Represents the report grouping. This field corresponds to the statement (stmt) field, which indicates the type of statement. The numeric value refers to the “R file” as posted on the EDGAR Web site. |
| line | Represents the tag’s presentation line order for a given report. Together with the statement and report field, presentation location, order and grouping can be derived. |
| stmt | The financial statement location to which the value of the “report” field pertains. |
| inpth | Value was presented “parenthetically” instead of in columns within the financial statements. For example: Receivables (net of allowance for bad debts of $200 in 2012) $700. |
| rfile | The type of interactive data file rendered on the EDGAR web site, H = .htm file, X = .xml file. |
| tag | The tag chosen by the filer for this line item. |
| version | The taxonomy identifier if the tag is a standard tag, otherwise adsh. |
| plabel | The text presented on the line item, also known as a “preferred” label. |
| negating | Flag to indicate whether the plabel is negating. |